Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

Novo­cure has se­cured the FDA’s bless­ing for an­oth­er use of its tu­mor treat­ing fields: ma­lig­nant pleur­al mesothe­lioma, a rare can­cer that de­vel­ops in the lin­ings of the lung and chest.

The NovoT­TF-100L Sys­tem is to be de­ployed with Eli Lil­ly’s Al­im­ta (peme­trexed) and a plat­inum-based chemother­a­py in the first-line treat­ment of un­re­sectable, lo­cal­ly ad­vanced or metasta­t­ic forms of the dis­ease. Cur­rent­ly, on­ly 10% to 20% of MPM pa­tients are can­di­dates for surgery to re­move the tu­mor, ac­cord­ing to Mary Hes­dorf­fer of the Mesothe­lioma Ap­plied Re­search Foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER